Michael Wells has had a long and distinguished career as an entrepreneur, healthcare investor, and chief executive.  He is the founder and Managing Director of Princeton Biopharma Capital Partners which he created for the purpose of providing growth capital to emerging health care companies.

He is also the acting Chairman and CEO of Fidelis Animal Health and non-executive Chairman of Kaleo, both portfolio companies of Princeton Biopharma Capital.  Prior to creating his investment company, he was the founder and CEO of Aton Pharma, a pharmaceutical company focused on rare diseases.  For his part in creating and growing this company he was named an Ernst & Young Entrepreneur of the Year in 2009 and in 2010 the company was acquired by Valeant Pharmaceuticals.   After selling Aton Pharma, he partnered with Cerberus Capital Management and invested in Covis Pharma Sarl where he was a board member for five years.  In 2020, Covis was sold to Apollo.  His career began at Merck & Co. where he held a range of sales and marketing positions over eight years.

Michael holds a Bachelor of Science and a Master of Science from the University of Pittsburgh in addition to an MBA from The Wharton School.  His current board appointments include Kaleo, Fidelis Animal Health, UPMC Hospital System and he is on the Board of Trustees at the University of Pittsburgh.